Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q3
$28K Buy
1,271
+20
+2% +$469 ﹤0.01% 1633
2015
Q2
$29K Buy
1,251
+36
+3% +$903 ﹤0.01% 1631
2015
Q1
$32K Sell
1,215
-5
-0.4% -$119 ﹤0.01% 1632
2014
Q4
$27K Sell
1,220
-173
-12% -$3.67K ﹤0.01% 1654
2014
Q3
$25K Buy
1,393
+140
+11% +$2.8K ﹤0.01% 1640
2014
Q2
$27K Buy
1,253
+263
+27% +$5.63K ﹤0.01% 1625
2014
Q1
$22K Sell
990
-6
-0.6% -$147 ﹤0.01% 1647
2013
Q4
$24K Buy
996
+189
+23% +$4.46K ﹤0.01% 1651
2013
Q3
$19K Buy
807
+177
+28% +$3.79K ﹤0.01% 1660
2013
Q2
$13K Buy
+630
New +$15.8K ﹤0.01% 1668

Other funds holding SRDX

OFI Advisors's SRDX Position: Q3 2015 in Review

OFI Advisors increased its Surmodics (SRDX) stake by 1.6% in Q3 2015, buying an estimated $469 and bringing the position to 1,271 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

OFI Advisors first reported a position in SRDX in Q2 2013 and has held it in 10 quarters since. The position peaked at $32K in Q1 2015. 125 funds tracked by Wall St. Rank hold SRDX as of Q3 2015.

  • OFI Advisors held 1,271 shares of Surmodics worth $28K as of Q3 2015.
  • OFI Advisors bought 20 Surmodics shares in Q3 2015, an estimated $469.
  • Surmodics made up ﹤0.01% of OFI Advisors's portfolio in Q3 2015, its #1633 holding.
  • OFI Advisors first reported a position in Surmodics in Q2 2013 and has held it in 10 quarters since.
  • OFI Advisors's Surmodics position peaked at $32K in Q1 2015.
  • 125 funds tracked by Wall St. Rank held Surmodics as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.